Sunho Biologics, Inc. (HKG:2898)

Hong Kong · Delayed Price · Currency is HKD

6.40

0.00 (0.00%)

Mar 6, 2026, 1:25 PM HKT

50.23% (1Y)

Market Cap	970.43M +51.2%
Revenue (ttm)	18.63K -99.9%
Net Income	-89.95M
EPS	-0.60
Shares Out	151.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	6.40
Previous Close	6.40
Day's Range	6.40 - 6.40
52-Week Range	3.99 - 8.60
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Sunho Biologics

Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer (CRC). The company also provides IAP0971 and IAE0972 immunocytokines, which have completed Phase I clinical trials for advanced solid tumors, i... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2018

Employees 128

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2898

Full Company Profile

Financial Performance

In 2024, Sunho Biologics's revenue was 38,000, a decrease of -99.78% compared to the previous year's 17.53 million. Losses were -79.97 million, -39.74% less than in 2023.

Financial numbers in CNY Financial Statements